immune_checkpoints

Immuno-oncology leverages immune checkpoints as targets. Biointron highlights antibodies advancing cancer therapy by modulating immune pathways.

ADCs and checkpoint inhibitors create synergy in oncology. Biointron explains how combining these modalities improves precision and patient outcomes.

Anti-mouse antibodies remain vital research tools. Biointron delivers reliable anti-mouse antibodies that support validation and consistent experimental results.

Discover how immune checkpoint inhibitors like PD-1 and CTLA-4 blockers are transforming cancer treatment, including synergies with antibody-based therapeutics.

Immune checkpoint blockade antibody therapy is an approach in cancer treatment that uses the body's immune system to target and destroy cancer cells. Immune checkpoints are regulatory pathways in immune cells that cancer cells exploit to evade detection. Key immune checkpoints include PD-1, PD-L1, and CTLA-4. By blocking these pathways, antibodies like pembrolizumab, nivolumab, and ipilimumab allow T-cells to recognize and attack cancer cells more effectively.

The Next-Gen Immuno-Oncology Conference 2024 in Boston featured advances in immunotherapy. Biointron shares insights driving future antibody-based treatments.